A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY To evaluate the efficacy of pregabalin compared with placebo for the treatment of chronic central neuropathic pain after spinal cord injury.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

NEUROMUSCULAR CHANGES IN SMALL FOR GESTATIONAL AGE (SGA-) CHILDREN DURING SOMATROPIN THERAPY - A PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER TRIAL (SGA-POWER STUDY) Primary objective is to determine whether growth hormone therapy improves motor- performance and coordinative skills in pre-pubertal individuals with SGA as defined by efficiency of muscular function.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTS To evaluate the safety and tolerability of voriconazole as primary treatment of invasive aspergillosis and rare molds such as Scedosporium or Fusarium species in immunocompromised pediatric subjects f...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The United Kingdom Glaucoma Treatment Study Not provided at time of registration

• Pays United Kingdom
• Organes Aucun
• Spécialités Aucune

A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis To assess the immunogenicity of etanercept manufactured using the high capacity process administered weekly in subjects with RA over 24 weeks.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer To assess progression free survival (PFS) of AG-013736 in combination with paclitaxel and carboplatin (Arm A) versus bevacizumab in combination with paclitaxel and carboplatin (Arm B).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS To compare progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib (at a starting dose of 37.5 mg daily continuous dosing) with those treated with placebo

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS 1) To compare the incidence of clinical biopsy-proven acute rejection (BPAR) (as interpreted by the central blinded pathologist) of combination regimens of CP-90,550 and mycophenolate mofetil (MMF) / ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) The primary objective of this study is to evaluate and compare the efficacy of 3 dose levels of PF-04236921 to placebo in subjects with active SLE using the SLE Responder Index (SRI).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Evaluation of the Effects of Roflumilast on Cardiac Repolarization, Pharmacokinetics, Safety, and Tolerability in Healthy Volunteers Not provided at time of registration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune